Shanghai Henlius Biotech (Henlius) and Sandoz have announced they will enter a strategic collaboration covering up to ten proposed monoclonal antibody (mAb) and ADC biosimilars, extending the companies’ existing oncology partnership and strengthening Sandoz’s global biosimilars pipeline.
Under the latest agreement, Sandoz will receive exclusive rights to register and commercialise the partnered products outside China, while Henlius will be responsible for development, manufacturing and supply.
The companies said the partnership will span from early development through regulatory submissions, manufacturing, launch and lifecycle management.
The initial portfolio comprises HLX05-N, a proposed cetuximab biosimilar; HLX16, a proposed evolocumab biosimilar; and a proposed belimumab biosimilar.
Sandoz also has an option to add HLXTE-HAase1001, a recombinant human hyaluronidase designed to enable the subcutaneous administration of biologic medicines.
The initial arrangements include an upfront payment, milestone payments and a non-refundable option fee totalling up to $322m.
Henlius said in its statement that it expects to record up to $100.5m in invoiced amounts during 2026.
Building a global biosimilars pipeline
The deal comes as Sandoz continues
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
